Rezultaty - Denis Moro‐Sibilot
- Rezultaty 1 - 20 Rezultaty od 68
- Idź do następnej strony
-
1
-
2
-
3
-
4
Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non–Small Cell Lung Cancer od Arnaud Van Den Broeck, Élisabeth Brambilla, Denis Moro‐Sibilot, Sylvie Lantuéjoul, Christian Brambilla, Béatrice Eymin, Saadi Khochbin, Sylvie Gazzéri
Wydane 2008Artigo -
5
-
6
Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis od Denis Moro‐Sibilot, Sylvie Lantuéjoul, Sami Diab, Nabila Moulaï, Axel Aubert, J. F. Timsit, Christian Brambilla, Pierre-Yves Brichon, E. Brambilla
Wydane 2007Artigo -
7
Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study od Anne McLeer‐Florin, Denis Moro‐Sibilot, A. Melis, Dimitri Salameire, Christine Lefebvre, Françoise Ceccaldi, Florence de Fraipont, Élisabeth Brambilla, Sylvie Lantuéjoul
Wydane 2011Artigo -
8
Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours od Sylvie Lantuéjoul, Jean‐Charles Soria, Denis Moro‐Sibilot, Luc Morat, Sylvie Veyrenc, P. Lorimier, Pierre-Yves Brichon, Laure Sabatier, Christian Brambilla, Élisabeth Brambilla
Wydane 2004Artigo -
9
IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype od J. Cadranel, Élisabeth Quoix, Laurence Baudrin, Pierre Mourlanette, Denis Moro‐Sibilot, Jean‐François Morère, Pierre-Jean Souquet, Jean‐Charles Soria, Franck Morin, B. Milleron
Wydane 2009Artigo -
10
Circulating free DNA concentration is an independent prognostic biomarker in lung cancer od Claire Tissot, Anne‐Claire Toffart, Stéphanie Villar, Pierre-Jean Souquet, P. Merle, Denis Moro‐Sibilot, M. Pérol, Jiří Zavadil, Christian Brambilla, Magali Olivier, S. Couraud
Wydane 2015Artigo -
11
Prognostic Impact of Paraneoplastic Cushing’s Syndrome in Small-Cell Lung Cancer od Hélène Nagy-Mignotte, Oxana Shestaeva, Lucile Vignoud, Pascale Guillem, Stéphane Ruckly, Olivier Chabre, L. Sakhri, M. Duruisseaux, Mireille Mousseau, Jean‐François Timsit, Denis Moro‐Sibilot
Wydane 2014Artigo -
12
<i>MET</i> exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung od Raphaël Saffroy, Vincent Fallet, Nicolas Girard, Julien Mazières, Denis Moro‐Sibilot, Sylvie Lantuéjoul, Isabelle Rouquette, Françoise Thivolet-Béjui, Thibaut Vieira, Martine Antoine, Jacques Cadranel, Antoinette Lemoine, Marie Wislez
Wydane 2017Artigo -
13
On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas od Lénaïg Mescam-Mancini, Sylvie Lantuéjoul, Denis Moro‐Sibilot, Isabelle Rouquette, Pierre-Jean Souquet, Clarisse Audigier-Valette, Jean‐Christophe Sabourin, C. Decroisette, L. Sakhri, Élisabeth Brambilla, Anne McLeer‐Florin
Wydane 2013Artigo -
14
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients od J-L. Pujol, Olivier Molinier, W. Ébert, Daurès Jp, Fabrice Barlési, G Buccheri, M Paesmans, Élisabeth Quoix, Denis Moro‐Sibilot, M Szturmowicz, J-M Bréchot, T. Muley, Jean‐Christophe Grenier
Wydane 2004Revisão -
15
Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity od Christian Brambilla, Julien Laffaire, Sylvie Lantuéjoul, Denis Moro‐Sibilot, Hélène Mignotte, François Arbib, Anne‐Claire Toffart, Fabien Petel, Pierre Hainaut, Sophie Rousseaux, Saadi Khochbin, Aurélien de Reyniès, Élisabeth Brambilla
Wydane 2014Artigo -
16
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus od Federico Cappuzzo, Denis Moro‐Sibilot, Oliver Gautschi, Ekaterini Boleti, Enriqueta Felip, Harry J.M. Groen, Paul Germonpré, Peter Meldgaard, Edurne Arriola, N. Steele, J. Fox, Patrick Schnell, Arne Engelsberg, Jürgen Wolf
Wydane 2014Revisão -
17
Osteoblastic Reaction in Non-small Cell Lung Carcinoma and its Association to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Response and Prolonged Survival od E. Pluquet, J. Cadranel, Anne Legendre, Michelle Beau Faller, Pierre Jean Souquet, Gérard Zalcman, M. Pérol, G. Fraboulet, Gerard Oliveiro, Florence de Fraipont, Élisabeth Quoix, Sylvie Lantuéjoul, B. Milleron, Denis Moro‐Sibilot
Wydane 2010Artigo -
18
High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets od Vincent Fallet, Raphaël Saffroy, Nicolas Girard, Julien Mazières, Sylvie Lantuéjoul, T. Vieira, Isabelle Rouquette, F. Thivolet-Béjui, Mony Ung, Virginie Poulot, L. Schlick, Denis Moro‐Sibilot, Martine Antoine, Jacques Cadranel, Antoinette Lemoine, Marie Wislez
Wydane 2015Artigo -
19
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics od Léonie Ferrer, Matteo Giaj Levra, Marie Brevet, Martine Antoine, Julien Mazières, Giulio Rossi, Rita Chiari, Virginie Westeel, M. Poudenx, J. Letreut, Radj Gervais, Giorgia Osman, Nicolas Girard, Anne Claire Toffart, Silvia Novello, Denis Moro‐Sibilot
Wydane 2018Artigo -
20
Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Non–Small-Cell Lung Cancer od Stéphane Vignot, Garrett M. Frampton, Jean‐Charles Soria, Roman Yelensky, Frédéric Commo, Christian Brambilla, Gary A. Palmer, Denis Moro‐Sibilot, Jeffrey S. Ross, Maureen Cronin, Fabrice André, Philip J. Stephens, Vladimir Lazar, Vincent A. Miller, Élisabeth Brambilla
Wydane 2013Artigo
Narzędzie wyszukiwania:
Podobne hasła
Medicine
Internal medicine
Lung cancer
Oncology
Cancer
Chemotherapy
Biology
Cancer research
Genetics
Gene
Pathology
Cisplatin
Surgery
Clinical endpoint
Immunotherapy
Confidence interval
Gastroenterology
Hazard ratio
Malignant pleural effusion
Crizotinib
Epidermal growth factor receptor
Randomized controlled trial
Adenocarcinoma
Nivolumab
Pemetrexed
Bevacizumab
Lung
Atezolizumab
Docetaxel
Environmental health